Literature DB >> 28063132

Evaluation of role of FV, FVIII and APLAs in the pathogenesis of APCR in FV Leiden negative DVT patients: a study in India.

Amit Sharma1, Kanwaljeet Singh2, Arijit Biswas3, Ravi Ranjan1, Kamal Kishor1, Ravi Kumar1, Hareram Pandey1, Vineet Kumar Kamal4, Renu Saxena5.   

Abstract

Resistance to APC (APCR) is a very important cause of thrombophilia and most frequently caused by the Leiden mutation. APCR is also seen in the absence of FV Leiden and associated with elevated levels of factor V (FV), factor VIII (FVIII) and antiphospholipid antibodies (APLAs). The aim of this prospective case control study was to find out the frequency and role of FV, FVIII and APLAs in the pathogenesis of APCR in FV Leiden negative deep vein thrombosis (DVT) patients in India. A total 30 APCR positive and FV Leiden negative patients with DVT and similar number of age and sex matched healthy controls were recruited. Significantly higher mean FVIII levels were observed in patients as compared to controls [patients: 132.3 ± 30.7 IU/ml, controls: 117.5 ± 17.7 IU/ml, p = 0.025]. A significant negative correlation was also observed between FVIII and APC ratio (Pearson correlation = 0.368, p = <0.001). Mean FV levels in patients [107.1 ± 13.1 IU/ml] and controls [102 ± 11.9 IU/ml] were not statistically significant (p = 0.119). Anti β2 glycoprotein I (Anti-β2-GPI, IgG) showed significant association with APCR phenotype (p = 0.050), unlike other factors such as protein C, protein S, lupus anticoagulant and anticardiolipin antibodies. The strong association of FVIII and anti-β2 GPI (IgG) antibodies with APCR phenotype is suggestive of incorporation of these factors in APCR positive DVT patients in the absence of FV Leiden mutation in India. However more studies in large sample size are required for setting up the proper investigation protocol in these patients.

Entities:  

Keywords:  Activated protein C resistance; Antiphospholipid antibodies; Deep vein thrombosis; Factor VIII

Mesh:

Substances:

Year:  2017        PMID: 28063132     DOI: 10.1007/s11239-016-1469-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  29 in total

1.  Absence of mutations at the APC interacting sites of factor VIII in Caucasians.

Authors:  Jens Brümmer; Janneke Groth; Raid Flayeh; Christoph Wagener; Roman Jung
Journal:  Thromb Haemost       Date:  2002-01       Impact factor: 5.249

Review 2.  Elevated factor VIII levels and the risk of thrombosis.

Authors:  P W Kamphuisen; J C Eikenboom; R M Bertina
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-05       Impact factor: 8.311

3.  Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels.

Authors:  P W Kamphuisen; F R Rosendaal; J C Eikenboom; R Bos; R M Bertina
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

4.  Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity.

Authors:  C M Henkens; V J Bom; J van der Meer
Journal:  Thromb Haemost       Date:  1995-10       Impact factor: 5.249

5.  Prevalence of Factor V Genetic Variants Associated With Indian APCR Contributing to Thrombotic Risk.

Authors:  Amit Sharma; Teena Bhakuni; Arijit Biswas; Ravi Ranjan; Ravi Kumar; Kamal Kishore; Manoranjan Mahapatra; Mohamad Aman Jairajpuri; Renu Saxena
Journal:  Clin Appl Thromb Hemost       Date:  2015-12-23       Impact factor: 2.389

6.  Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response.

Authors:  J O'Donnell; A D Mumford; R A Manning; M Laffan
Journal:  Thromb Haemost       Date:  2000-01       Impact factor: 5.249

7.  A novel mutation of Arg306 of factor V gene in Hong Kong Chinese.

Authors:  W P Chan; C K Lee; Y L Kwong; C K Lam; R Liang
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

8.  Resistance to activated protein C as a basis for venous thrombosis.

Authors:  P J Svensson; B Dahlbäck
Journal:  N Engl J Med       Date:  1994-02-24       Impact factor: 91.245

9.  Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus.

Authors:  Junzo Nojima; Hirohiko Kuratsune; Etsuji Suehisa; Tomio Kawasaki; Takashi Machii; Teruo Kitani; Yoshinori Iwatani; Yuzuru Kanakura
Journal:  Br J Haematol       Date:  2002-08       Impact factor: 6.998

10.  Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women.

Authors:  Sara Sedano-Balbás; Mark Lyons; Brendan Cleary; Margaret Murray; Geraldine Gaffney; Majella Maher
Journal:  J Pregnancy       Date:  2011-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.